EN DE
Watch Cynata Therapeutics Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cynata Therapeutics Limited (CYYNF) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of Cynata Therapeutics Limited stock $0.01, price $0.01, upside +0.4%, quality 44 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Australia

CT Cynata Therapeutics Limited logo Thin data Nov 10, 2026

Cynata Therapeutics Limited

CYYNF · US

The stock is already about fairly priced and weak company.

Get notified free when this changes
Ranks above peers (3/4) 
Fair value $0.0072 · Fairly valued 
Quality 44/100 
Negative equity (buybacks among others) 
Revenue last quarter 10% below a year ago. 
Weak Growth (revenue 3y +1.1 %/yr in AUD) 
Negative free cash flow 
Narrow moat 12/100 · thin data
Thin data 
Estimate⚠ Thinly traded
Watch Cynata Therapeutics Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.4000 $0.0014 Fair Value $0.0072 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.0014 – $0.4000 · fair‑value band $0.0071 – $0.0074 · the $0.0072 price screens below the $0.0072 fair value. As of Nov 10, 2026.

Follow Cynata Therapeutics in your weekly email

Every Wednesday you see whether Cynata Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Show moreShow less

The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease.

It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs.

Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013.

Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

Stock analysis

Cynata Therapeutics Limited (CYYNF) currently trades at $0.0072, while our estimate is $0.0072, so the stock looks roughly fairly valued today (gap 0.4%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.0071 (bear) to $0.0074 (bull), the price of $0.0072 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Cynata Therapeutics Limited reported revenue of A$1.7M in FY2026 versus A$7.8M in FY2022, a compound −31.5%/yr. Reported net income was −A$9.1M in FY2026.

Key figures

Market cap $1.7M Micro · P/S ratio 1.02 · EPS (TTM) $−0.0200 · Return on equity −341% · Return on assets (EBIT) −168% (5-year average) · Operating margin −466% · Revenue (TTM) A$1.7M · Revenue growth (YoY) −10.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 97% below its 52-week high and 414% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 0%, CYYNF screens cheaper than that median.

Fair Value

Bear $0.0071 Fair Value $0.0072 Bull $0.0074
Price $0.0072 · Upside +0.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 49
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−9.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.1%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−375.6% (2021) → −424.3% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch CYYNF, get fair value alerts →

Compare Cynata Therapeutics Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 3/4 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 44 · Above median
Fair Value upside +0.4% · Top 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Growth and dividend
Revenue growth (quarter YoY) −10.0% · Below median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 1.48× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)34 · sector 0
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 21

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs CYYNF
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs CYYNF
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs CYYNF
argenx SE ARGX $950.95 $908.40 −4% vs CYYNF
CSL Limited CSL A$199.55 A$186.49 −7% vs CYYNF
Moderna, Inc MRNA $215.27 $135.64 −37% vs CYYNF
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs CYYNF
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs CYYNF
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs CYYNF
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs CYYNF

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cynata Therapeutics Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cynata Therapeutics Limited Fair Value". https://www.fairvalue-calculator.com/stock/CYYNF

Frequently asked questions

Is Cynata Therapeutics Limited (CYYNF) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.0072 versus the last price from Oct 30, 2026 of $0.0072, about +0% upside (fairly valued).
What is the fair value of CYYNF?
Our estimate for Cynata Therapeutics Limited is $0.0072 (as of Nov 10, 2026), built from audited fundamentals. Last price (from Oct 30, 2026): $0.0072.
What is the quality score of CYYNF?
Cynata Therapeutics Limited has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cynata Therapeutics Limited (CYYNF)?
Our calculated price target is the estimate of $0.0072 (as of Nov 10, 2026). Cautious scenario $0.0071, optimistic scenario $0.0074. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cynata Therapeutics Limited stock forecast for 2026?
Our estimate puts fair value at $0.0072, about +0% upside versus the last price from Oct 30, 2026 of $0.0072 (fairly valued). Cautious scenario $0.0071, optimistic scenario $0.0074. The calculation is refreshed regularly with new filings.
What is the revenue of Cynata Therapeutics Limited (CYYNF)?
Cynata Therapeutics Limited reported trailing-twelve-month revenue of about A$1.7M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Cynata Therapeutics Limited (CYYNF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cynata Therapeutics Limited it is $0.0072 per share (as of Nov 10, 2026), against a price of $0.0072.
Is Cynata Therapeutics Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CYYNF trades below its calculated fair value: price $0.0072, fair value $0.0072, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CYYNF?
No. The price is what the market pays today ($0.0072); the fair value is what the company's own numbers justify ($0.0072). For Cynata Therapeutics Limited the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cynata Therapeutics Limited worth?
The market values Cynata Therapeutics Limited at about $1.7M (market capitalisation, as of Nov 10, 2026). Per share that is $0.0072; our models calculate a fair value of $0.0072 per share.
What do the bullish and bearish scenarios say about CYYNF?
Our models span a range for Cynata Therapeutics Limited: cautious scenario $0.0071, base $0.0072, optimistic $0.0074 per share (as of Nov 10, 2026, price $0.0072). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cynata Therapeutics Limited (CYYNF)?
Balance-sheet figures for Cynata Therapeutics Limited (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is CYYNF from its 52-week high?
Cynata Therapeutics Limited trades at $0.0072, about 97% below its 52-week high of $0.2225 and 414% above the low of $0.0014 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0072 is for.
Which stocks are comparable to Cynata Therapeutics Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cynata Therapeutics Limited stock attractive at the current price?
The data as of Nov 10, 2026: price $0.0072, calculated fair value $0.0072 (+0%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Cynata Therapeutics Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cynata Therapeutics Limited (CYYNF)?
The latest price we hold is from Oct 30, 2026 and stands at $0.0072. Our estimate is $0.0072, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cynata Therapeutics Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0071 to $0.0074), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Cynata Therapeutics Limited

How large is the market capitalisation of Cynata Therapeutics Limited (CYYNF)?
The market capitalisation of Cynata Therapeutics Limited is $1.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cynata Therapeutics Limited (CYYNF)?
The price-to-sales ratio of Cynata Therapeutics Limited is 1.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cynata Therapeutics Limited (CYYNF)?
Earnings per share at Cynata Therapeutics Limited are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cynata Therapeutics Limited (CYYNF)?
The return on equity (ROE) of Cynata Therapeutics Limited is −341% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cynata Therapeutics Limited (CYYNF)?
On an EBIT basis the return on assets of Cynata Therapeutics Limited is −168% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cynata Therapeutics Limited (CYYNF)?
The operating margin of Cynata Therapeutics Limited is −466% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cynata Therapeutics Limited (CYYNF)?
Revenue at Cynata Therapeutics Limited is down 10.0% versus a year earlier (3y avg +1.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cynata Therapeutics Limited (CYYNF) generate?
The free cash flow of Cynata Therapeutics Limited is −A$6.7M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cynata Therapeutics Limited (CYYNF) hold?
Cynata Therapeutics Limited holds more cash than debt, A$896K net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Cynata Therapeutics Limited in the live analysis

One click puts Cynata Therapeutics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.